Archives: Month: December 2024
-
December 28, 2024
Expanding Treatment Options for Low-Risk DCIS: First COMET Results are Released
The first results of the U.S-based Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) trial, a phase III randomized clinical trial comparing different management strategies for low-risk DCIS, were released earlier this month. The findings were published in JAMA and JAMA Oncology and were presented at the 2024 San Antonio Breast Cancer Symposium. The key takeaway from the study is that women with low-risk DCIS who underwent active monitoring instead of surgery were no more likely to develop invasive breast cancer in the affected breast after two years. The findings represent a first step toward a safe…
-
December 16, 2024
New Study Maps Molecular Clues Behind Which DCIS Cases Progress to Invasive Breast Cancer
Due to improved screening, DCIS now makes up about one-quarter of all breast cancer diagnoses. However, most cases of DCIS never progress to invasive breast cancer (IBC), meaning that many women undergo unnecessary aggressive treatments like surgery, radiation, and hormone therapy. Molecular predictors of which DCIS cases will progress remain poorly understood. To better understand which DCIS cases are likely to progress to IBC, researchers studied nearly 200 breast tissue samples from DCIS patients who either stayed healthy or later developed invasive cancer. They analyzed the samples’ genes, DNA changes, and other molecular patterns. The results were published earlier this month in Breast Cancer Research. The study concluded that DCIS…
